Reilly Financial Advisors LLC Has $90,000 Stock Holdings in Bristol-Myers Squibb Co (NYSE:BMY)

Reilly Financial Advisors LLC lessened its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 13.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 1,984 shares of the biopharmaceutical company’s stock after selling 306 shares during the period. Reilly Financial Advisors LLC’s holdings in Bristol-Myers Squibb were worth $90,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. James Investment Research Inc. grew its stake in shares of Bristol-Myers Squibb by 36.5% in the 1st quarter. James Investment Research Inc. now owns 819 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 219 shares during the period. Lowe Brockenbrough & Co. Inc. grew its position in Bristol-Myers Squibb by 0.5% during the 1st quarter. Lowe Brockenbrough & Co. Inc. now owns 43,384 shares of the biopharmaceutical company’s stock worth $2,070,000 after acquiring an additional 220 shares during the last quarter. Squar Milner Financial Services LLC grew its position in Bristol-Myers Squibb by 5.6% during the 1st quarter. Squar Milner Financial Services LLC now owns 4,209 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 223 shares during the last quarter. Modera Wealth Management LLC grew its position in Bristol-Myers Squibb by 4.3% during the 4th quarter. Modera Wealth Management LLC now owns 5,567 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 229 shares during the last quarter. Finally, Clear Harbor Asset Management LLC grew its position in Bristol-Myers Squibb by 2.4% during the 1st quarter. Clear Harbor Asset Management LLC now owns 9,637 shares of the biopharmaceutical company’s stock worth $460,000 after acquiring an additional 229 shares during the last quarter. 77.60% of the stock is owned by institutional investors and hedge funds.

In other news, insider Karen Murphy Santiago sold 3,065 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $47.56, for a total value of $145,771.40. Following the completion of the transaction, the insider now owns 3,066 shares in the company, valued at approximately $145,818.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Theodore R. Samuels II acquired 5,000 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was bought at an average price of $47.29 per share, with a total value of $236,450.00. Following the acquisition, the director now directly owns 27,000 shares in the company, valued at $1,276,830. The disclosure for this purchase can be found here. 0.13% of the stock is owned by company insiders.

A number of equities research analysts recently commented on the company. BMO Capital Markets increased their price target on Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Goldman Sachs Group assumed coverage on Bristol-Myers Squibb in a research report on Tuesday, May 28th. They set a “buy” rating and a $54.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on Bristol-Myers Squibb in a report on Friday, May 3rd. They set an “overweight” rating and a $62.00 price objective on the stock. Barclays raised Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $53.00 to $55.00 in a report on Friday, May 3rd. Finally, UBS Group reduced their price objective on Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a report on Thursday, June 13th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $55.45.

BMY stock traded up $0.30 during trading hours on Friday, reaching $45.50. 10,300,630 shares of the stock were exchanged, compared to its average volume of 13,343,362. The firm’s 50-day simple moving average is $45.69. The company has a market cap of $74.34 billion, a P/E ratio of 11.43, a price-to-earnings-growth ratio of 2.21 and a beta of 0.71. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.06 by $0.12. The company had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.10 billion. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. Bristol-Myers Squibb’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.01 EPS. Equities analysts expect that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were issued a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 3.60%. The ex-dividend date of this dividend was Wednesday, July 3rd. Bristol-Myers Squibb’s payout ratio is 41.21%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: Trading Strategy Methods and Types

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.